Graystone Company (OTC: GYST) announced the completion of its Fucoidan Longevity Booster, a key product in its Immune Support, Anti-Inflammatory & Anti-Aging line. Independent research suggests fucoidan may prevent cancer cell growth and enhance immune responses. Unlike traditional Fucoidan, Graystone's nano-formulation promises improved absorption and efficacy. The wellness supplement market is projected to grow to $386.29 billion by 2027, indicating strong future potential for Graystone's offerings.
Graystone Company, Inc. (OTC: GYST) has announced the upcoming launch of its first product, the Fucoidan Longevity Booster, set for July/August 2021. This innovative product features a nano Fucoidan Extract aimed at enhancing absorption and offers various health benefits, including potential anti-inflammatory, anti-cancer, and anti-aging properties. Research from reputable sources suggests fucoidan's efficacy in boosting immune responses and possibly aiding in cancer treatment. The company is finalizing product formulas, which underscores its commitment to the longevity and wellness market.
Graystone Company (OTC: GYST) has completed a reverse merger with NutraGyst, Inc., shifting its focus to developing products in the Fertility and Longevity & Wellness sectors. The company aims to create high-quality, plant-based supplements that are Non-GMO, gluten-free, and lactose-free. Product formulas and packaging are currently being finalized, with an expected launch of the first product in July/August 2021. The merger is part of Graystone's strategy to innovate in the health supplement market.